Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00452530
First received: March 23, 2007
Last updated: July 8, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare the efficacy of apixaban with that of enoxaparin (Lovenox®) in the prevention of these clots. The safety of apixaban will also be studied.


Condition Intervention Phase
Deep Vein Thrombosis
Pulmonary Embolism
Drug: Enoxaparin
Drug: Apixaban
Drug: Enoxaparin-matching placebo
Drug: Apixaban-matching placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period [ Time Frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study drug ] [ Designated as safety issue: No ]
    Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization.Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.


Secondary Outcome Measures:
  • Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period [ Time Frame: Day of randomization to later of 2 days after last dose or 14 days after first dose; 14 days after randomization for those who did not receive study ] [ Designated as safety issue: No ]
    Event rate=Number of events divided by the number of patients evaluated. Intended treatment period starts on the day of randomization, and for those who received study drug, ends at the later of 2 days after last dose or 14 days after the first dose of study drug; for randomized patients who did not receive study drug, the period ends 14 days after randomization; for randomized patients who did not receive study drug, the period ends 14 days after randomization. Venous thromboembolic event (VTE)=nonfatal pulmonary embolism (PE), symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death=fatal PE or sudden death for which VTE could not be excluded as a cause.

  • Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM [ Time Frame: Days 1 to 12 ] [ Designated as safety issue: Yes ]
    Event rate=Number of events divided by number of patients evaluated. Adjusted difference of event rates takes into consideration type of surgery as a stratification factor. Bleeding Criteria: Major bleeding=an event consisting of clinically overt bleeding accompanied by a decrease in hemoglobin of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. CRNM bleeding= clinically overt bleeding; that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event; that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding; or a change in antithrombic treatment.

  • Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome [ Time Frame: Days 1 through 12 + 2 days (nonserious AEs, bleeding AES) or 30 days (SAES, deaths) after last dose of study drug ] [ Designated as safety issue: Yes ]
    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Bleeding AEs=all serious or nonserious bleeding-related AEs.


Other Outcome Measures:
  • Summary of Laboratory Marked Abnormalities on Hematology and Liver and Kidney Function Test Results During the Treatment Period (Patients With Available Measurements) [ Time Frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up ] [ Designated as safety issue: Yes ]
    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal; abs=absolute. Hemoglobin (g/dL): >2 decrease from preRx value or value <=8; hematocrit (%): <0.75*preRx; platelets: <100*10^9 cells/L; erythrocytes (*10^6 cells/μL): <0.75*preRx; leukocytes: <0.75*LLN or >1.25*ULN, or if preRx <LLN, use <0.8*preRx or >ULN if preRx >ULN use >1.2*preRx or <LLN; abs basophils: >400/mm^3; abs eosinophils: > 0.750*10^3 cells/µL; abs lymphocytes: <0.750*10*3 cells/ µL or >7.50*10^3 c/ µL; abs monocytes > 2000/mm^3; abs neutrophils: <1.0*10^3 cells/μL; ALP (U/L): >2*ULN; ALT, AST (U/L): >3*ULN; U/L; bilirubin, direct (mg/dL): >1.5*ULN; bilirubin, total (mg/dL): >2*ULN; BUN (mg/dL): >2*ULN; creatinine (mg/dL): >1.5*ULN.

  • Summary of Laboratory Marked Abnormalities in Electrolyte and Other Clinical Test Results During the Treatment Period (Patients With Available Measurements) [ Time Frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (±5 days) of follow-up ] [ Designated as safety issue: Yes ]
    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Calcium, total (mg/dL): <0.8*LLN or >1.2*ULN, or if preRx<LLN use <0.75*preRx or >ULN if preRx >ULN use >1.25*preRx or <LLN; chloride, serum (mEq/L): <0.9*LLN or >1.1*ULN, or if preRx<LLN use <0.9*preRx or >ULN if preRx>ULN use >1.1*preRx or <LLN; bicarbonate (mEq/L): <0.75*LLN or >1.25*ULN, or if preRx < LLN use <0.75*preRx or >ULN if preRx >ULN use >1.25*preRx or < LLN; potassium, serum (mEq/L): <0.9* LLN or >1.1*ULN, or if preRx<LLN use <0.9 *preRx or >ULN if preRx>ULN use >1.1*preRx or <LLN; sodium, serum (mEq/L): <0.95*LLN or >1.05*ULN, or if preRx <LLN use <0.95*preRx or >ULN if preRx>ULN use >1.05*preRx or <LLN; protein, total (g/dL): <0.9*LLN or >1.1*ULN, or if preRx <LLN use 0.9*preRx or >ULN if preRx >ULN use 1.1*preRx or <LLN; CK (U/L): >5*ULN; uric acid (mg/dL): >1.5*ULN, or if preRx >ULN use >2*preRx; glucose, fasting serum (mg/dL): <0.8*LLN or >1.5*ULN, or if preRx <LLN use <0.8*preRx or >ULN.

  • Summary of Laboratory Marked Abnormalities in Urinalysis Results During the Treatment Period-Treated Subjects With Available Measurements (Urinalysis) [ Time Frame: Randomization to Days 2, 3, 4, and 12 (±2 days) and at Days 42 and 72 (± 5 days) of follow-up ] [ Designated as safety issue: Yes ]
    preRX=pretreatment. Blood, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; glucose, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; protein, urine: If missing preRx use ≥ 2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; Red blood cells , urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4; white blood cells, urine: If missing preRx use ≥2, or if value ≥4, or if preRx=0 or 0.5 use ≥2, or if preRx=1 use ≥3, or if preRx=2 or 3 use ≥4.


Enrollment: 3221
Study Start Date: June 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apixaban, 2.5 mg BID + Placebo
Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
Drug: Apixaban
2.5 mg, administered twice daily as tablets, for 12 days
Other Name: BMS-562247
Drug: Enoxaparin-matching placebo
Administered once daily by subcutaneous injection
Active Comparator: Enoxaparin, 40 mg QD + Placebo
Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
Drug: Enoxaparin
40 mg, administered once daily by subcutaneous injection, for 12 days
Other Name: Lovenox®
Drug: Apixaban-matching placebo
Oral tablet administered twice daily

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  • Patients scheduled for either elective unilateral or same-day bilateral total knee replacement surgery (TKR) or a revision of at least 1 component of a TKR
  • Patients willing and able to undergo bilateral ascending contrast venography

Key Exclusion Criteria

  • Known or suspected hereditary or acquired bleeding or coagulation disorders in the participant or his or her first-degree relative
  • Known or suspected history of heparin-induced thrombocytopenia
  • Known coagulopathy
  • Active bleeding or at high risk for bleeding
  • Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
  • Active hepatobiliary disease
  • Alcohol and/or substance abuse within the past year
  • Any condition for which, in the opinion of the investigator, surgery or administration of an anticoagulant was contraindicated
  • Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg
  • Clinically significant laboratory abnormalities at the enrollment visit:

    • Hemoglobin <10 g/dL
    • Platelet count <100,000/mm^3
    • Creatinine clearance <30 mL/min, as estimated by the method of Cockcroft and Gault
    • Alanine aminotransferase or aspartate aminotransferase level >2*upper limit of normal (ULN) or a total bilirubin ≥1.5*ULN (unless an alternative causative factor such as Gilbert's syndrome was identified)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452530

  Hide Study Locations
Locations
Austria
Local Institution
Graz, Austria, 8036
Local Institution
Innsbruck, Austria, 6020
Local Institution
Linz, Austria, 4010
Local Institution
Wels, Austria, 4600
Local Institution
Wien, Austria, 1090
Local Institution
Wien, Austria, 1130
Local Institution
Wiener Neustadt, Austria, 2700
Belgium
Local Institution
Antwerpen, Belgium, 2020
Local Institution
Hasselt, Belgium, 3500
Brazil
Local Institution
Belo Horizonte - Mg, Minas Gerais, Brazil, 30130
Local Institution
Sao Paulo, Brazil, 04023
Chile
Local Institution
Santiago, Metropolitana, Chile, 7500922
Local Institution
Santiago, Metropolitana, Chile, 8330033
China, Beijing
Local Institution
Beijing, Beijing, China, 100035
Local Institution
Beijing, Beijing, China, 100835
China, Shandong
Local Institution
Qingdao, Shandong, China, 266003
China, Shanghai
Local Institution
Shanghai, Shanghai, China, 200025
Local Institution
Shanghai, Shanghai, China, 200233
Local Institution
Shanghai, Shanghai, China, 200011
Colombia
Local Institution
Bogota, Colombia
Local Institution
Bogota, Colombia, XXXXX
Local Institution
Cali, Colombia, - - - - -
Local Institution
Medelin, Colombia, -----
Czech Republic
Local Institution
Brno, Czech Republic, 662 50
Local Institution
Chomutov, Czech Republic, 430 12
Local Institution
Pardubice, Czech Republic, 532 03
Local Institution
Prague 8, Czech Republic, 180 81
Local Institution
Uherske Hradiste, Czech Republic, 686 68
Denmark
Local Institution
Hellerup, Denmark, 2900
Local Institution
Hvidovre, Denmark, 2650
Local Institution
Kolding, Denmark, 6000
Local Institution
Viborg, Denmark, 8800
France
Local Institution
Monaco, France, 98000
Local Institution
Nice, France, 06200
Local Institution
Paris, France, 75019
Local Institution
Paris, France, 75679
Local Institution
Paris, France, 75014
Local Institution
Saint-Saulve, France, 59880
Germany
Local Institution
Bad Mergentheim, Germany, 97980
Local Institution
Bochum, Germany, 44791
Local Institution
Brandenburg, Germany, 14770
Local Institution
Dresden, Germany, 01307
Local Institution
Frankfurt, Germany, 65929
Local Institution
Frankfurt Am Main, Germany, 60528
Local Institution
Halle/S, Germany, 06112
Local Institution
Kremmen Ot Sommerfeld, Germany, 16766
Local Institution
Rheinfelden, Germany, 79618
Local Institution
Witten, Germany, 58455
Hungary
Local Institution
Szeged, Hungary, 6725
Local Institution
Szekszard, Hungary, 7100
India
Local Institution
Ahmedabad, Gujarat, India, 380054
Local Institution
Ludhiana, Punjab, India, 141001
Local Institution
Bangalore, India, 560034
Local Institution
Baroda, India, 390007
Local Institution
Mangalore, India, 575001
Israel
Local Institution
Jeruselem, Israel, 91031
Local Institution
Petach-Tikva, Israel, 49372
Local Institution
Safed, Israel, 13110
Local Institution
Tel Aviv, Israel, 64239
Local Institution
Tel Hashomer, Israel, 52621
Italy
Local Institution
Abano Terme (Pd), Italy, 35031
Local Institution
Bologna, Italy, 40136
Local Institution
Pordenone, Italy, 33170
Local Institution
Roma, Italy, 00168
Local Institution
San Donato Milanese (Mi), Italy, 20097
Korea, Republic of
Local Institution
Jeonnam, Korea, Republic of, 519-809
Local Institution
Seoul, Korea, Republic of, 110-744
Local Institution
Seoul, Korea, Republic of, 138-736
Local Institution
Seoul, Korea, Republic of, 136-705
Malaysia
Local Institution
Kuala Lumpur, Malaysia, 56000
Local Institution
Kuala Lumpur, Malaysia, 50586
Mexico
Local Institution
Zapopan, Jalisco, Mexico, 45200
Local Institution
Hermosillo, Sonora, Mexico, 83190
Local Institution
Aguascalientes, Mexico, 20010
Local Institution
San Luis Potosi, Mexico, 78340
Local Institution
Veracruz, Mexico, 91700
Norway
Local Institution
Alesund, Norway, 6026
Local Institution
Gjettum, Norway, 1346
Local Institution
Kongsvinger, Norway, 2212
Philippines
Local Institution
Manila, Philippines, 1000
Local Institution
Quezon City, Philippines, 1114
Local Institution
Quezon City, Philippines, 1102
Poland
Local Institution
Bytom, Poland, 41-902
Local Institution
Gdansk, Poland, 80-803
Local Institution
Warszawa, Poland, 03-242
Local Institution
Wroclaw, Poland, 50-556
Russian Federation
Local Institution
Chelyabinsk, Russian Federation, 454021
Local Institution
Kazan, Russian Federation, 420029
Local Institution
Lipetsk, Russian Federation, 398035
Local Institution
Moscow, Russian Federation, 115522
Local Institution
Rostov-Na-Donu, Russian Federation, 344010
Local Institution
Saint Petersburg, Russian Federation, 199106
Local Institution
Saint Petersburg, Russian Federation, 194354
Local Institution
Saint Petersburg, Russian Federation, 195427
Local Institution
Saint Petersburg, Russian Federation, 193312
Local Institution
Samara, Russian Federation, 443095
Singapore
Local Institution
Singapore, Singapore, 169608
Local Institution
Singapore, Singapore, 529889
South Africa
Local Institution
Randburg, Free State, South Africa, 2194
Local Institution
Johannesburg, Gauteng, South Africa, 2193
Local Institution
Johannesburg, Gauteng, South Africa, 2031
Local Institution
Pretoria, Gauteng, South Africa, 0083
Local Institution
Somerset West, Western Cape, South Africa, 7130
Local Institution
Tygerberg, Western Cape, South Africa, 7505
Local Institution
Worcester, Western Cape, South Africa, 6850
Spain
Local Institution
Badalona-Barcelona, Spain, 08916
Local Institution
Barcelona, Spain, 08035
Local Institution
Barcelona, Spain, 08006
Local Institution
Barcelona, Spain, 08024
Local Institution
Madrid, Spain, 28034
Local Institution
Santiago De Compostela, Spain, 15706
Local Institution
Valencia, Spain, 46010
Sweden
Local Institution
Boras, Sweden, 501 82
Ukraine
Local Institution
Cherkassy, Ukraine, 18009
Local Institution
Chernivtsy, Ukraine, 58013
Local Institution
Dnipropetrovsk, Ukraine, 49005
Local Institution
Ivano-Frankivsk, Ukraine, 76008
Local Institution
Kyiv, Ukraine, 01601
Local Institution
Kyiv, Ukraine, 04107
Local Institution
Sevastopol, Ukraine, 99018
United Kingdom
Local Institution
London, Greater London, United Kingdom, SE5 9PJ
Local Institution
Epsom, Surrey, United Kingdom, KT18 7EG
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00452530     History of Changes
Other Study ID Numbers: CV185-047, EUdraCT: 2006-006896-19
Study First Received: March 23, 2007
Results First Received: April 14, 2014
Last Updated: July 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Prevention of deep vein thrombosis and pulmonary embolism after total knee replacement surgery

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Thrombosis
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Enoxaparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on August 01, 2014